ASX Announcement 2 Dec 2021

The following was announced via ASX on 2 Dec 2021. Please click to review the full announcement.  


ASX Announcement 9 Nov 2021

The following was announced via ASX on 9 Nov 2021. Please click to review full announcement.  


Q&A with Chief Development Officer Yalia Jayalakshmi, Ph.D.

In this video, Chief Development Officer Yalia Jayalakshmi, Ph.D. explains why she joined Imagion Biosystems, the urgency of the company's mission, and the…


Imagion Biosystems Half-Year Results for the First Half of 2021 and Appendix 4D

1H2021 Highlights: Enrolment for the Phase I HER2 Breast Cancer Study commences Initiation of research for prostate cancer imaging supported by CSIRO funds…


Imagion Biosystems Enters Agreement to Develop Nanocrystals for Treating Breast Cancer

Imagion Biosystems is pleased to announce it has entered into a Joint Development Agreement with Global Cancer Technology (GCT), to develop GCT’s novel…


Quarterly Activity Report and Appendix 4C for 30 June 2021

Imagion has released the Quarterly Activity Report and Appendix 4C for the period ending on 30 June 2021. The report highlights that during the quarter the…


Presentation Visuals from 28th May 2021 Annual General Meeting

The presentation visuals from the 28th May 2021 Annual General Meeting are now available. Download here.


Imagion Biosystems Receives A$2.6 Million R&D Tax Incentive

Imagion Biosystems Limited is pleased to announce that it has received its 2020 R&D tax incentive claim of $2,612,159 from the Australian Taxation…


First Patient Enrolled in Phase I MagSense® HER2+ Breast Cancer Study

This week Imagion Biosystems has announced we have enrolled our first patient into our first clinical study. This is an important step for our Phase I…


Bob Proulx Speaks with The Market Herald

The Chairman and CEO of Imagion Biosystems, Bob Proulx, recently spoke with The Market Herald on a significant transaction in the molecular imaging market, and…